Stock Events

Stock Events

Immuron Limited 

$1.8000
23
+$0.69+62.16% 20:00 Today
-$0.02-1.11%21:38After hours

Statistics

Day High
1.99
Day Low
1.54
52W High
2.39
52W Low
0.677
Volume
121,633,356
Avg. Volume
33,558
Mkt Cap
14.53M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

28AugExpected
Q3 2023
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
Next
-0.01
-0
-0
0
Expected EPS
-0.00008854912
Actual EPS
N/A

Financials

-71.89%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
4.64MRevenue
-3.33MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IMRN. It's not an investment recommendation.
NVIDIA
3
NVDA
Alphabet
3
GOOG
Chevron
3
CVX
Vanguard S&P 500 UCITS - Acc
3
VUAG.LSE

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sorrento Therapeutics
SRNE
Mkt Cap385,896
Sorrento Therapeutics works on therapies for autoimmune diseases, which overlaps with Immuron's work on immune modulation.
Theravance Biopharma
TBPH
Mkt Cap885.21M
Theravance Biopharma develops treatments for inflammatory conditions, competing in the immune-mediated therapeutic area similar to Immuron.
Rigel Pharmaceuticals
RIGL
Mkt Cap868.24M
Rigel Pharmaceuticals focuses on discovering and developing novel small-molecule drugs for immune disorders, directly competing with Immuron's product portfolio.
Adma Biologics
ADMA
Mkt Cap2.09B
ADMA Biologics specializes in immune globulin products, which are in the same therapeutic area as Immuron's immunotherapy products.
AIM ImmunoTech
AIM
Mkt Cap7.87M
AIM ImmunoTech works on therapies for diseases of immune dysregulation, aligning closely with Immuron's focus on immune system modulation.
Brainstorm Cell Therapeutics
BCLI
Mkt Cap11.92M
Brainstorm Cell Therapeutics is involved in developing treatments for autoimmune diseases, which competes with Immuron's focus on immune system health.
Cytodyn
CYDY
Mkt Cap315.04M
CytoDyn is focused on developing innovative treatments for autoimmune and inflammatory diseases, directly competing with Immuron's therapeutic focus.
Protalix BioTherapeutics
PLX
Mkt Cap204.65M
Protalix BioTherapeutics engages in developing treatments for disorders caused by enzyme deficiencies, which indirectly competes with Immuron's work on immune-related diseases.

About

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
Show more...
CEO
Steven George Lydeamore
Employees
7
Country
Australia
ISIN
US45254U1016
WKN
000A2DTD8

Listings

STU
DE
ANWA.STU
STU
DE
ANW.STU
MU
DE
ANWA.MU
MU
DE
ANW.MU

0 Comments

Share your thoughts

FAQ

What is Immuron Limited stock price today?▼
The current price of IMRN is $1.80 USD — it has increased by +62.16% in the past 24 hours. Watch Immuron Limited stock price performance more closely on the chart.
What is Immuron Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Immuron Limited stocks are traded under the ticker IMRN.
Is Immuron Limited stock price growing?▼
IMRN stock has risen by +56.52% compared to the previous week, the month change is a +66.67% rise, over the last year Immuron Limited has showed a -4.76% decrease.
What is Immuron Limited market cap?▼
Today Immuron Limited has the market capitalization of 14.53M
When is the next Immuron Limited earnings date?▼
Immuron Limited is going to release the next earnings report on February 19, 2027.
What is Immuron Limited revenue for the last year?▼
Immuron Limited revenue for the last year amounts to 4.64M USD.
What is Immuron Limited net income for the last year?▼
IMRN net income for the last year is -3.33M USD.
How many employees does Immuron Limited have?▼
As of September 04, 2026, the company has 7 employees.
In which sector is Immuron Limited located?▼
Immuron Limited operates in the Health & Wellness sector.
When did Immuron Limited complete a stock split?▼
The last stock split for Immuron Limited was on November 17, 2014 with a ratio of 1:40.
Where is Immuron Limited headquartered?▼
Immuron Limited is headquartered in Carlton, Australia.